And, in January, Viking Therapeutics reported the peer-reviewed publication of Phase II data for its dual GLP-1/GIP receptor agonist VK2735 and confirmed that the program has progressed into the VANQUISH Phase III registrational studies, with one pivotal trial fully enrolled and a second expected to complete enrollment in early 2026
The treatment effects of insulin rescue therapy used the inherent insulin therapy profile of Cardiff diabetes model [18] (Table 1)
Let your doctor know about any other meds youre on to avoid interactions, and report any side effects ASAP
The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499
The preclinical evidence for TB-500 is substantial (including a landmark Nature paper), but translation to human data is not yet established
In this episode, Lori and Ashley break down the basics of macronutrients, why protein is your BFF, and how counting macros can actually simplify your life, not complicate it